Timothy Barabe Joins HeartFlow’s Board of Directors

HeartFlow Holding Inc. has welcomed a new board member.

The company recently appointed Timothy Barabe to its Board of Directors.
 
Barabe has more than 30 years of experience in the life sciences industry, across a broad range of financial and strategic roles. Most recently, he served as chief financial officer (CFO) and executive vice president at Affymetrix Inc., where he led the company’s financial functions as well as the treasury, investor relations, and information technology departments. Previously, he served as senior vice president and CFO at Human Genome Sciences, where he worked with the leadership team to drive the financial strategy and operations of the company. For more than 20 years, he held senior international executive roles in finance, general management, and strategic planning at Novartis AG. His roles included CFO of the Sandoz Generics Business Unit, president of the CIBA Vision Corporation Specialty Lens Business Franchise, and group vice president and CFO of CIBA Vision Corporation.

“We are honored to have an accomplished leader like Tim join the HeartFlow Board,” said William C. Weldon, board chairman of HeartFlow. “Tim’s background and expertise in financial strategy, operations and stewardship will add important perspectives to the Board as we enter our next phase of growth.”
 
Barabe currently serves as a board member and Audit Committee chair of Selecta Biosciences Inc., and on the board of Vigilant Biosciences, a privately-held medical device company. He previously served on the Boards of Veeva Systems Inc., ArQule, Opexa Therapeutics, Autonomous Technologies and BioCure Inc. As an active philanthropist, Barabe is involved in various charitable causes and served on the board of Project Open Hand, a San Francisco-based non-profit organization focused on serving nutritious meals to vulnerable populations from 2014 to 2020.
 
“I am thrilled to join the Board of Directors for HeartFlow as the company is at a key inflection point in its growth trajectory,” said Barabe. “I look forward to leveraging my experience and working with the team to make HeartFlow’s game-changing technology broadly available to more patients worldwide.”
 
Barabe earned a bachelor’s of business administration degree in finance from the University of Massachusetts (Amherst) and an MBA from the University of Chicago.
 
Starting with a standard coronary computed tomography angiogram (CTA), the HeartFlow Analysis leverages algorithms trained using deep learning (a form of AI) and highly trained analysts to create a digital, personalized 3D model of the heart. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and provides FFRct values along the coronary arteries. This information is used by physicians in evaluating the impact a blockage may be having on blood flow and determine the optimal course of treatment for each patient. A positive FFRct value (≤0.80) indicates that a coronary blockage is impeding blood flow to the heart muscle to a degree which may warrant invasive management. Data demonstrating the safety, efficacy and cost-effectiveness of the HeartFlow Analysis have been published in more than 500 peer-reviewed publications, including long-term data out to five years. The HeartFlow Analysis offers the highest diagnostic performance available from a non-invasive test.¹ To date, clinicians around the world have used the HeartFlow Analysis for more than 100,000 patients to aid in the diagnosis of heart disease.
 
HeartFlow’s non-invasive HeartFlow FFRct Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow’s technology incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRct Analysis is commercially available in the United States, U.K., Canada, Europe, and Japan. 

Reference
¹ Driessen, R., et al. J Am Coll Cardiol. 2019;73(2),161-73